EA200501206A1 - Производные от сурвивина пептиды и их применение - Google Patents

Производные от сурвивина пептиды и их применение

Info

Publication number
EA200501206A1
EA200501206A1 EA200501206A EA200501206A EA200501206A1 EA 200501206 A1 EA200501206 A1 EA 200501206A1 EA 200501206 A EA200501206 A EA 200501206A EA 200501206 A EA200501206 A EA 200501206A EA 200501206 A1 EA200501206 A1 EA 200501206A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
derivations
survivin peptides
survivin
tumor
Prior art date
Application number
EA200501206A
Other languages
English (en)
Other versions
EA008026B1 (ru
Inventor
Эйвинд Пер Тхор Стратен
Мадс Халд Андерсен
Original Assignee
СУРВАК АпС
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/354,090 external-priority patent/US20040210035A1/en
Application filed by СУРВАК АпС filed Critical СУРВАК АпС
Publication of EA200501206A1 publication Critical patent/EA200501206A1/ru
Publication of EA008026B1 publication Critical patent/EA008026B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464448—Regulators of development
    • A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent

Abstract

Рестриктированные по МНС классу I, производные опухолеассоциированного антигена - сурвивина, которые способны связываться с молекулами HLA класса I при высокой аффинности, способны элиситировать INF-γ-продуцирующие клетки в популяции PBL пациентов, страдающих раком, и способны к in situ обнаружению цитотоксических Т-клеток в опухолевой ткани, терапевтическая и диагностическая композиция, включающая пептид, и ее применение.Отчет о международном поиске был опубликован 2004.10.28.
EA200501206A 2003-01-30 2004-01-30 Производные от сурвивина пептиды и их применение EA008026B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/354,090 US20040210035A1 (en) 2002-01-30 2003-01-30 Survivin-derived peptides and use thereof
US10/715,417 US7892559B2 (en) 2002-01-30 2003-11-19 Survivin-derived peptides and use thereof
PCT/DK2004/000062 WO2004067023A2 (en) 2003-01-30 2004-01-30 Survivin-derived peptides and use thereof

Publications (2)

Publication Number Publication Date
EA200501206A1 true EA200501206A1 (ru) 2006-02-24
EA008026B1 EA008026B1 (ru) 2007-02-27

Family

ID=32829435

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501206A EA008026B1 (ru) 2003-01-30 2004-01-30 Производные от сурвивина пептиды и их применение

Country Status (16)

Country Link
US (4) US7892559B2 (ru)
EP (5) EP2857034B1 (ru)
JP (1) JP5121143B2 (ru)
CN (2) CN1767848B (ru)
AT (3) ATE454159T1 (ru)
AU (1) AU2004208469B2 (ru)
CA (1) CA2513104C (ru)
DE (3) DE602004032483D1 (ru)
EA (1) EA008026B1 (ru)
ES (2) ES2339193T3 (ru)
HK (2) HK1087335A1 (ru)
MX (1) MXPA05008128A (ru)
NO (1) NO333213B1 (ru)
NZ (1) NZ541510A (ru)
PT (3) PT2092938E (ru)
WO (1) WO2004067023A2 (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040210035A1 (en) * 2002-01-30 2004-10-21 Straten Eivind Per Thor Survivin-derived peptides and use thereof
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
KR101284237B1 (ko) 2003-11-19 2013-07-09 수르벡 에이피에스 Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암 환자에 대한 그들의 용도
JP4602006B2 (ja) * 2004-06-29 2010-12-22 独立行政法人科学技術振興機構 サバイビン由来のｈｌａ−ａ２４結合性癌抗原ペプチド
EP2657338B1 (en) * 2005-01-25 2015-07-08 NEC Corporation HLA-binding peptide, and DNA fragment and recombinant vector coding for said HLA-binding peptide
AU2006209951B2 (en) 2005-02-04 2011-04-14 Survac Aps Survivin peptide vaccine
AU2011203536B2 (en) * 2005-02-04 2012-11-15 Survac Aps Survivin peptide vaccine
AU2011203535B2 (en) * 2005-02-04 2012-10-11 Survac Aps Survivin peptide vaccine
US20060276423A1 (en) * 2005-04-18 2006-12-07 Rachel Altura Survivin-directed RNA interference-compositions and methods
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
FR2891462B1 (fr) * 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
WO2009012460A1 (en) * 2007-07-19 2009-01-22 Health Research, Inc. Survivin peptides as cancer vaccines
US8580269B2 (en) 2007-07-19 2013-11-12 Health Research, Inc. Survivin peptides for autoimmune therapies
JP5546448B2 (ja) * 2008-03-31 2014-07-09 株式会社バイオイミュランス ＭＨＣクラスＩＩ分子に提示されるサーバイビン（Ｓｕｒｖｉｖｉｎ）の部分ペプチドとその利用法
ES2532896T5 (es) * 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
EP2172211B1 (en) * 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
CA2821582A1 (en) 2010-12-14 2012-06-21 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
BR112013023978B1 (pt) * 2011-03-21 2021-09-08 Atlantic Cancer Research Institute Polipeptídeo com afinidade por proteínas de choque térmico e seu uso em diagnóstico de doença infecciosa, produção de resposta imune e tratamento de câncer, bem como ácido nucleico, composição e método de fracionamento de substância para pesquisa ou análise clínica de amostra biológica
EP2854842A4 (en) * 2012-05-25 2016-11-02 Agenus Inc IDENTIFICATION OF BREAST CANCER CLASS I MHC PHOSPHOPEPTIDE ANTIGENS USING SHLA TECHNOLOGY AND COMPLEMENTARY ENRICHMENT STRATEGIES
EP2872532A4 (en) 2012-07-10 2016-04-13 Oncotherapy Science Inc CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH
ES2702622T3 (es) 2013-03-27 2019-03-04 Immunovaccine Technologies Inc Método para mejorar la eficacia de una vacuna de survivina en el tratamiento de cáncer
JP6697386B2 (ja) 2013-11-22 2020-05-20 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 改変された高親和性ヒトｔ細胞受容体
AU2015289644A1 (en) 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
JP2018509384A (ja) 2015-01-06 2018-04-05 イミューノヴァクシーン テクノロジーズ インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リピドａ模倣体、調製方法、及びその使用
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
US20180162913A1 (en) * 2015-05-01 2018-06-14 Immunovaccine Technologies Inc. Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
JP6989134B2 (ja) 2015-11-18 2022-01-05 イミューノヴァクシーン テクノロジーズ インコーポレイテッドImmunovaccine Technologies Inc. ポリｉ：ｃポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物
GB201604755D0 (en) * 2016-03-21 2016-05-04 Vaxeal Res Sas Immunogenic compositions
KR20190057345A (ko) 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
WO2018065625A2 (en) 2016-10-07 2018-04-12 Enterome Immunogenic compounds for cancer therapy
JP7116278B2 (ja) 2016-10-07 2022-08-10 エンテローム エスエー 癌治療のための免疫原性化合物
CN110049774A (zh) 2016-10-07 2019-07-23 恩特罗姆公司 肿瘤相关抗原表位的小型生物群序列变体
KR102591136B1 (ko) 2017-03-03 2023-10-17 트레오스 바이오 리미티드 집단 기반 면역원성 펩타이드 확인 플랫폼
JP6993677B2 (ja) * 2017-11-08 2022-01-13 学校法人日本医科大学 犬におけるがんの予防、がんの治療またはがんの転移の予防のためのがんペプチドワクチン
LT3773689T (lt) * 2018-04-11 2023-01-25 Enterome S.A. Antigeniniai peptidai, skirti vėžio prevencijai ir gydymui
SG11202101888YA (en) 2018-09-04 2021-03-30 Treos Bio Ltd Peptide vaccines
FR3087448B1 (fr) 2018-10-23 2023-10-13 Pdc Line Pharma Lignee pdc modifiee pour secreter une cytokine
US20220125903A1 (en) * 2018-11-19 2022-04-28 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
CN111440246B (zh) * 2020-04-16 2022-03-18 成都仕康美生物科技有限公司 靶向HLA-B的嵌合抗原受体、编码基因、CAR-Tregs细胞及其制备方法、用途
KR20230044133A (ko) * 2021-09-24 2023-04-03 주식회사 차백신연구소 종양 연관 항원으로부터 유래된 펩타이드 및 리포펩타이드와 면역활성물질로 구성되는 아쥬번트를 포함하는 항암 백신 조성물 및 이의 용도
CN115477686B (zh) * 2022-09-22 2024-01-30 北海黑珍珠海洋生物科技有限公司 一种具有美白功效的珍珠贝活性肽及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
ATE378406T1 (de) 1992-08-31 2007-11-15 Ludwig Inst Cancer Res Vom mage-3-gen en abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
AU736587B2 (en) * 1996-11-20 2001-08-02 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
WO1999050637A2 (en) * 1998-03-27 1999-10-07 Ludwig Institute For Cancer Research Isolated multimeric complexes useful in analysis of t cells, peptides useful in making the complexes, and uses thereof
AU768834B2 (en) * 1998-04-01 2004-01-08 Yale University A method for selectively modulating the interactions between survivin and tubulin
AU4990999A (en) 1998-07-14 2000-02-07 Jenner Biotherapies, Inc. Survivin, and peptides thereof, as an anti-cancer vaccine
ES2747357T3 (es) * 2001-03-14 2020-03-10 Dako Denmark As Construcciones de moléculas MHC y sus usos para el diagnóstico y terapia
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US20040210035A1 (en) * 2002-01-30 2004-10-21 Straten Eivind Per Thor Survivin-derived peptides and use thereof
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
KR101284237B1 (ko) 2003-11-19 2013-07-09 수르벡 에이피에스 Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암 환자에 대한 그들의 용도

Also Published As

Publication number Publication date
CN101906148B (zh) 2013-08-28
NO333213B1 (no) 2013-04-08
ATE406906T1 (de) 2008-09-15
EP2857034B1 (en) 2017-04-19
AU2004208469A1 (en) 2004-08-12
AU2004208469B2 (en) 2010-05-13
ES2339193T3 (es) 2010-05-17
EA008026B1 (ru) 2007-02-27
NO20053999L (no) 2005-10-28
JP5121143B2 (ja) 2013-01-16
EP2005966B1 (en) 2010-01-06
MXPA05008128A (es) 2005-12-05
WO2004067023A3 (en) 2004-10-28
HK1087335A1 (en) 2006-10-13
CA2513104A1 (en) 2004-08-12
US8318174B2 (en) 2012-11-27
EP2857034A1 (en) 2015-04-08
CN101906148A (zh) 2010-12-08
US7892559B2 (en) 2011-02-22
DE602004016287D1 (de) 2008-10-16
CA2513104C (en) 2012-12-11
EP2092938B1 (en) 2011-04-27
ATE506962T1 (de) 2011-05-15
EP1587532B1 (en) 2008-09-03
DE602004032483D1 (de) 2011-06-09
PT1587532E (pt) 2008-11-25
US20040176573A1 (en) 2004-09-09
ES2312956T3 (es) 2009-03-01
CN1767848A (zh) 2006-05-03
US20130115216A1 (en) 2013-05-09
NO20053999D0 (no) 2005-08-29
PT2092938E (pt) 2011-06-07
EP2359841A3 (en) 2011-11-23
EP2359841B1 (en) 2014-11-05
USRE48522E1 (en) 2021-04-20
EP1587532A2 (en) 2005-10-26
EP2359841A2 (en) 2011-08-24
EP2005966A1 (en) 2008-12-24
ATE454159T1 (de) 2010-01-15
PT2005966E (pt) 2010-03-08
NZ541510A (en) 2008-04-30
US9534030B2 (en) 2017-01-03
DE602004025059D1 (de) 2010-02-25
JP2006517529A (ja) 2006-07-27
US20070148184A1 (en) 2007-06-28
CN1767848B (zh) 2010-04-28
EP2092938A1 (en) 2009-08-26
HK1126668A1 (en) 2009-09-11
WO2004067023A2 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
EA200501206A1 (ru) Производные от сурвивина пептиды и их применение
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
ATE451388T1 (de) Tumorassoziierte peptide, die promiskuitiv an humane leukozytenantigen- (hla-) moleküle der klasse ii binden
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
DE602005015990D1 (de) Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden
ATE512160T1 (de) T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen
PE20050712A1 (es) Anticuerpos rg1
PH12015501467A1 (en) Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
WO2002053700A3 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
ATE509025T1 (de) ßMIT MHC-KLASSE-I-PEPTIDEPITOPEN KOVALENT VERKN PFTES MEMBRANVERANKERTES BETA2-MIKROGLOBULINß
NO20181511A1 (no) Survivin-avledede peptider og bruken av dem
DE69828791D1 (de) Das antigen ha-1
UY26170A1 (es) Antigeno (c42) asociados a tumores
AR023794A1 (es) Antigeno asociado con tumores
UY26127A1 (es) Antígeno asociado con tumores
CY1114151T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα ως προς την κιναση τυροσινης πρωτεϊνης 7 (ρτκ7) και η χρηση αυτων
CY1113958T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε φουκοζυλ-gμ1 και μεθοδοι για τη χρηση αντι-φουκοζυλ-gμ1
CY1115252T1 (el) Αντισωμα εναντιον cd22 για την θεραπευτικη αγωγη ογκου αιματοποιητικης προελευσης
AR019387A1 (es) Polipeptido aislado, polinucleotido aislado, vector de expresion, celula huesped, composicion farmaceutica, vacuna, anticuerpo aislado, kit de diagnostico,oligonucleotido, metodo para inhibir el desarrollo de cancer, proteinas de fusion, metodo para separar celulas tumorales de una muestra biologica

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM